Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01014962 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus
A Phase 1 study, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01014962 is a Phase 1 study that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 24 participants.
The verdict
NCT01014962, a Phase 1 study, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine an upper dose of albaconzole to be administered in a Thorough QTc study.
Interventions
- DRUG Placebo
- DRUG Albaconozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-08-24 |
| Est. Completion | 2009-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01014962
The ClinicalTrials.gov registry entry for NCT01014962 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01014962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01014962 about?
NCT01014962 is a clinical study titled "A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus". The purpose of this study is to determine an upper dose of albaconzole to be administered in a Thorough QTc study.
What is the current status of trial NCT01014962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-08-24. Estimated completion is 2009-12-04.
What interventions are being tested in trial NCT01014962?
The interventions under investigation include: Placebo (DRUG), Albaconozole (DRUG).
Who is sponsoring clinical trial NCT01014962?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.